Key Takeaways:
- Lilly’s Kisunla, priced at $32,000 annually, receives FDA approval for early-stage Alzheimer’s.
- Kisunla offers potential cost benefits and convenience over Eisai’s Leqembi.
- Analysts forecast Alzheimer’s drug sales to surge to $13 billion by 2030.
What Happened?
Eli Lilly & Co.’s new Alzheimer’s treatment, Kisunla, has received FDA approval, becoming the second drug in the U.S. to slow the progression of Alzheimer’s. This milestone comes after years of clinical trials and regulatory delays. Kisunla will compete with Eisai Co.’s Leqembi, which launched in early 2023.
Priced at $32,000 for the first year, Kisunla’s cost is higher than Leqembi’s $26,500, but doctors can discontinue Kisunla if brain plaques drop to minimal levels. This potential reduction in treatment duration could lower overall costs. Shares of Lilly dipped 0.8% despite the approval, while Biogen, Eisai’s partner, saw a 1.3% decline.
Why It Matters?
The FDA’s approval of Kisunla is a significant win for Eli Lilly and its investors. Alzheimer’s disease affects 6 million Americans, and the demand for effective treatments is high. The convenience of Kisunla’s monthly infusions and the potential to stop treatment if effective make it an attractive option.
According to Howard Fillit, co-founder of the Alzheimer’s Drug Discovery Foundation, “Less frequent dosing and the potential to stop treatment are a really big deal.” Moreover, this approval could pave the way for more insurance coverage and broader market acceptance, as emphasized by Joanne Pike, CEO of the Alzheimer’s Association.
What’s Next?
Investors should watch how Kisunla’s market introduction unfolds, especially its competition with Leqembi. Both drugs face logistical and reimbursement challenges, but Kisunla’s less frequent dosing and potential cost benefits may give it an edge.
Analysts predict significant growth in the Alzheimer’s drug market, with sales expected to reach $13 billion by 2030 from the current $250 million. The next steps involve monitoring Medicare coverage and hospital readiness to handle the necessary safety testing and treatment protocols.
